Development of regenerative therapy of central nervous system, using with asialo-erythropoietin
Project/Area Number |
20791020
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Cerebral neurosurgery
|
Research Institution | Osaka Medical College |
Principal Investigator |
MIKI Yoshihito 大阪医科大学, 医学部, 非常勤医師 (50454541)
|
Project Period (FY) |
2008 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | エリスロポイエチン / 短半減期エリスロポイエチン / アシアロエリスロポイエチン / 脳梗塞 / 脳虚血 / 神経保護 / 神経再生 / 選択的神経細胞死 |
Research Abstract |
Systemic administration of high-dose recombinant human erythropoietin(rhEPO) is known to attenuate ischemic injury. However, high-dose rhEPO might aggravate ischemic lesions by increasing blood viscosity because of its erythropoietic effects. Asialoerythropoietin(asialoEPO), an EPO derivative with an extremely short plasma half-life, has considerably lesser erythropoietic effect than that of naive EPO. We attempted to determine whether asialoEPO exerts the same neuroprotective effect as naive EPO in a gerbil transient forebrain ischemia model, and resulting multiple dosing of asialoEPO, like EPO, could protect the hippocampal CA1 neurons from ischemic damage without affecting erythropoiesis. This data suggested that asialoEPO would be novel neuro-protective agent in the future.
|
Report
(6 results)
Research Products
(5 results)